CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing
identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will
participate in a treatment phase and a follow-up phase.